Olaparib for advanced breast cancer-MedSci.cn

Olaparib for advanced breast cancer

Griguolo, G; Dieci, MV; Miglietta, F; Guarneri, V; Conte, P

Conte, P (corresponding author), Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy.; Conte, P (corresponding author), Ist Oncol Veneto IRCCS, Div Oncol 2, Padua, Italy.

FUTURE ONCOLOGY, 2020; 16 (12): 717

Abstract

Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. I......

Full Text Link